Harvest Healthcare Ltd

harvesthealthcare.co.uk

Harvest Healthcare Ltd is the leading manufacturer and distributor of quality healthcare equipment to the NHS, Care Home and Community markets, throughout the UK and internationally. We are continually developing our range of products to deliver a complete solution for all modern care environments. Focused on meeting the ever-evolving needs of patients, Harvest deliver quality and value for money.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GSK STARTS PHASE 2/3 STUDY OF COVID-19 ANTIBODY TREATMENT WITH VIR BIOTECHNOLOGY

GlobeNewswire | September 01, 2020

news image

-Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization. The aim of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study, which will enroll approximatel...

Read More

MedTech

SPECTRUMX CONFIRMS NEXT STEP IN CLINICAL DEVELOPMENT OF RESPIRATORY DRUG CANDIDATE SPX-001 AFTER MHRA MEETING

SpectrumX | November 25, 2022

news image

SpectrumX, a UK-based healthcare and pharmaceutical company announces that following a constructive scientific advice meeting with the Medicines and Healthcare products Regulatory Agency on Monday, 14th November, the Company is prepared to move forward with the next stage in clinical development of its respiratory drug candidate SPX-001. Per regulatory guidelines, SpectrumX will submit a combined Clinical Trial and Ethics Committee application for a placebo-controlled phase Ib inf...

Read More

Medical

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

news image

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More

MedTech

GENSCRIPT LAUNCHES EXPEDITED MRNA SERVICE FOR RESEARCH AND PRE-CLINICAL APPLICATIONS

Genscript | August 18, 2022

news image

GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of a new research use only and pre-clinical messenger RNA synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks. mRNA provides new therapeutic opportunities for a range of diseases, and s...

Read More
news image

GSK STARTS PHASE 2/3 STUDY OF COVID-19 ANTIBODY TREATMENT WITH VIR BIOTECHNOLOGY

GlobeNewswire | September 01, 2020

-Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization. The aim of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study, which will enroll approximatel...

Read More
news image

MedTech

SPECTRUMX CONFIRMS NEXT STEP IN CLINICAL DEVELOPMENT OF RESPIRATORY DRUG CANDIDATE SPX-001 AFTER MHRA MEETING

SpectrumX | November 25, 2022

SpectrumX, a UK-based healthcare and pharmaceutical company announces that following a constructive scientific advice meeting with the Medicines and Healthcare products Regulatory Agency on Monday, 14th November, the Company is prepared to move forward with the next stage in clinical development of its respiratory drug candidate SPX-001. Per regulatory guidelines, SpectrumX will submit a combined Clinical Trial and Ethics Committee application for a placebo-controlled phase Ib inf...

Read More
news image

Medical

ALTERITY THERAPEUTICS LAUNCHES ATH434 PHASE 2 CLINICAL TRIAL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE SYSTEM ATROPHY

Alterity Therapeutics | June 03, 2022

Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand. MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...

Read More
news image

MedTech

GENSCRIPT LAUNCHES EXPEDITED MRNA SERVICE FOR RESEARCH AND PRE-CLINICAL APPLICATIONS

Genscript | August 18, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of a new research use only and pre-clinical messenger RNA synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks. mRNA provides new therapeutic opportunities for a range of diseases, and s...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us